TNSN99173A1 - DELIVERY OF ACTIVE AGENT IN THE FORM OF DRY POWDER - Google Patents

DELIVERY OF ACTIVE AGENT IN THE FORM OF DRY POWDER

Info

Publication number
TNSN99173A1
TNSN99173A1 TNTNSN99173A TNSN99173A TNSN99173A1 TN SN99173 A1 TNSN99173 A1 TN SN99173A1 TN TNSN99173 A TNTNSN99173 A TN TNSN99173A TN SN99173 A TNSN99173 A TN SN99173A TN SN99173 A1 TNSN99173 A1 TN SN99173A1
Authority
TN
Tunisia
Prior art keywords
active agent
dry powder
delivery
lung
hygroscopic
Prior art date
Application number
TNTNSN99173A
Other languages
French (fr)
Inventor
Clark Andrew
Kuo Mai-Chang
Lalor Cecily
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of TNSN99173A1 publication Critical patent/TNSN99173A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

=J167-LA PRESENTE INVENTION PORTE SUR DES COMPOSITIONS SOUS FORME DE PARTICULES ET SUR DES METHODES D'ADMINISTRATION D'UN AGENT ACTIF DANS LE POUMON D'UN PATIENT HUMAIN. LA FORMULATION D'AGENT ACTIF EST SOUS FORME D'UNE POUDRE SECHE ET MONTRE (i) UNE FAIBLE ABSORPTION D'HUMIDITE, ET (ii) UNE RESISTANCE AU DEVELOPPEMENT HYGROSCOPIQUE, SURTOUT SOUS DES CONDITIONS SIMULEES DU POUMON. I172= J167-THE PRESENT INVENTION RELATES TO COMPOSITIONS IN THE FORM OF PARTICLES AND TO METHODS OF ADMINISTERING AN ACTIVE AGENT IN THE LUNG OF A HUMAN PATIENT. THE ACTIVE AGENT FORMULATION IS IN THE FORM OF DRY POWDER AND SHOWS (i) LOW MOISTURE ABSORPTION, AND (ii) RESISTANCE TO HYGROSCOPIC DEVELOPMENT, ESPECIALLY UNDER SIMULATED LUNG CONDITIONS. I172

TNTNSN99173A 1998-09-14 1999-09-14 DELIVERY OF ACTIVE AGENT IN THE FORM OF DRY POWDER TNSN99173A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
TNSN99173A1 true TNSN99173A1 (en) 2005-11-10

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99173A TNSN99173A1 (en) 1998-09-14 1999-09-14 DELIVERY OF ACTIVE AGENT IN THE FORM OF DRY POWDER

Country Status (44)

Country Link
EP (1) EP1117442A1 (en)
JP (1) JP2002524535A (en)
KR (1) KR20010075063A (en)
CN (1) CN1317977A (en)
AP (1) AP1374A (en)
AR (1) AR022090A1 (en)
AU (1) AU753014B2 (en)
BG (1) BG105430A (en)
BR (1) BR9913722A (en)
CA (1) CA2343920A1 (en)
CO (1) CO5130023A1 (en)
CZ (1) CZ2001829A3 (en)
DZ (1) DZ2892A1 (en)
EA (1) EA003476B1 (en)
EE (1) EE200100151A (en)
GE (1) GEP20043257B (en)
GT (1) GT199900156A (en)
HK (1) HK1042231A1 (en)
HN (1) HN1999000159A (en)
HR (1) HRP20010189A2 (en)
HU (1) HUP0103837A3 (en)
ID (1) ID28845A (en)
IL (2) IL141562A0 (en)
IS (1) IS5878A (en)
LT (1) LT4897B (en)
LV (1) LV12658B (en)
MA (1) MA25590A1 (en)
MY (1) MY129282A (en)
NO (1) NO20011251L (en)
NZ (1) NZ510168A (en)
OA (1) OA11781A (en)
PA (1) PA8481901A1 (en)
PE (1) PE20001061A1 (en)
PL (1) PL195574B1 (en)
SA (1) SA99200718B1 (en)
SK (1) SK3442001A3 (en)
TN (1) TNSN99173A1 (en)
TR (1) TR200101182T2 (en)
TW (1) TWI226248B (en)
UA (1) UA76085C2 (en)
UY (1) UY25711A1 (en)
WO (1) WO2000015262A1 (en)
YU (1) YU24201A (en)
ZA (1) ZA200101995B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874483B2 (en) 1999-06-09 2012-02-15 ロバート イー． シーバース Supercritical fluid assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
JP2005503425A (en) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
NZ535323A (en) 2002-02-25 2008-02-29 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
JP2006513238A (en) * 2002-12-19 2006-04-20 ファルマシア・コーポレーション Non-hygroscopic formulations containing hygroscopic drugs
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CN101098678A (en) 2004-04-23 2008-01-02 锡德克斯公司 Dpi formulation containing sulfoalkyl ether cyclodextrin
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
RU2007137121A (en) * 2005-03-09 2009-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) PARTICLE AND PREPARATION CONTAINING THE SPECIFIED PARTICLE
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP2581078B1 (en) 2005-10-26 2014-12-10 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
US20100093875A1 (en) * 2006-10-25 2010-04-15 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
EP1925295A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
MX2009010988A (en) 2007-04-13 2010-03-15 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease.
JP2011502125A (en) 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー A new class of treatments that promote small molecule diffusion
ES2661215T3 (en) 2009-05-20 2018-03-28 Aeras Viral compositions; immunogens; spray dried; stable
CA2765697C (en) 2009-06-22 2019-11-12 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
IN2014MN02359A (en) * 2012-05-03 2015-08-14 Janssen R & D Ireland
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US20180043585A9 (en) * 2013-09-20 2018-02-15 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
MX2017005692A (en) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Powder formulation.
CN115089569A (en) 2016-03-24 2022-09-23 扩散药品有限公司 Use of bipolar trans carotenoids in conjunction with chemotherapy and radiation therapy for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
EP0611567B1 (en) * 1992-06-12 2002-08-28 Teijin Limited Ultrafine powder for inhalation and production thereof
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
PT954282E (en) * 1997-01-16 2005-06-30 Massachusetts Inst Technology PREPARATION OF PARTICLES FOR INHALATION
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
BG105430A (en) 2001-12-29
NZ510168A (en) 2003-09-26
AU6039799A (en) 2000-04-03
NO20011251D0 (en) 2001-03-13
LT2001021A (en) 2001-11-26
CO5130023A1 (en) 2002-02-27
PA8481901A1 (en) 2002-04-25
PE20001061A1 (en) 2000-10-08
WO2000015262A1 (en) 2000-03-23
TR200101182T2 (en) 2001-09-21
GT199900156A (en) 2001-03-07
HK1042231A1 (en) 2002-08-09
CA2343920A1 (en) 2000-03-23
SA99200718B1 (en) 2006-11-04
LT4897B (en) 2002-02-25
IL141562A0 (en) 2002-03-10
AP2001002093A0 (en) 2001-03-31
EA003476B1 (en) 2003-06-26
MY129282A (en) 2007-03-30
HRP20010189A2 (en) 2005-04-30
NO20011251L (en) 2001-04-17
DZ2892A1 (en) 2003-12-15
IL141562A (en) 2007-07-24
BR9913722A (en) 2001-05-29
CN1317977A (en) 2001-10-17
PL195574B1 (en) 2007-10-31
PL346768A1 (en) 2002-02-25
ZA200101995B (en) 2002-03-11
OA11781A (en) 2005-07-26
HUP0103837A3 (en) 2002-11-28
LV12658B (en) 2001-09-20
UY25711A1 (en) 1999-11-17
YU24201A (en) 2003-08-29
AU753014B2 (en) 2002-10-03
HUP0103837A2 (en) 2002-05-29
GEP20043257B (en) 2004-06-25
MA25590A1 (en) 2002-12-31
KR20010075063A (en) 2001-08-09
HN1999000159A (en) 1999-11-11
AP1374A (en) 2005-02-28
IS5878A (en) 2001-03-05
TWI226248B (en) 2005-01-11
EA200100300A1 (en) 2001-10-22
JP2002524535A (en) 2002-08-06
AR022090A1 (en) 2002-09-04
UA76085C2 (en) 2006-07-17
ID28845A (en) 2001-07-05
EP1117442A1 (en) 2001-07-25
EE200100151A (en) 2002-06-17
LV12658A (en) 2001-05-20
SK3442001A3 (en) 2001-11-06
CZ2001829A3 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
TNSN99173A1 (en) DELIVERY OF ACTIVE AGENT IN THE FORM OF DRY POWDER
TNSN99188A1 (en) DELIVERY OF ATOMIZED ACTIVE AGENT BY MODULATION OF FLOW RESISTANCE
Shinkar et al. Drug delivery from the oral cavity: A focus on mucoadhesive
Haberman et al. Contact dermatitis from beryllium in dental alloys
TNSN99038A1 (en) DELIVERY OF AN ATOMIZED ACTIVE AGENT
Sas et al. The intra-oral distribution of unstimulated and chewing-gum-stimulated parotid saliva
DE60326887D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM TOXIN AND HUMAN SERUM ALBUMIN
KR970705979A (en) Spray-dried microparticles as therapeutic vehicles as therapeutic agents
ATE232382T1 (en) PHARMACEUTICAL COMPOSITIONS WITH RAPID RELEASE OF ACTIVE INGREDIENTS
CA2038097A1 (en) Method and composition for coiontophoresis
WO2001041707A3 (en) Modulation of in vivo glutamine and glycine levels in the treatment of autism
ATE264102T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE WITH RAPID TRANSMUCOSAL ABSORPTION
MX9605940A (en) Bio-aromatic compounds carrying an adamantyl group in ortho, pharmaceutical and cosmetic compositions containing them and utilization.
BR9611815A (en) Chewing tablet with effervescent action
WO2008013929A3 (en) Anti-migraine oral spray formulations and methods
DE60327843D1 (en) MEDICAMENT FORMULATIONS WITH DELAYED RELEASE WITH A CARRIER PEPTIDE
Somasundaram et al. In vitro absorption of [14C] leucine during inflammation and the effect of antiinflammatory drugs in the jejunum of rats
Oz et al. A model for chronic mucosal inflammation in IBD and periodontitis
DE3669106D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING FLAVANOLIGNANES AND PHOSPHOLIPIDES AS ACTIVE INGREDIENTS.
EE04038B1 (en) Formoterol inhalation dosage form, bulk density 0.28 to 0.38 g / ml, method of preparation and use
TR200201262T2 (en) Bubble gum compositions.
JP2004513093A5 (en)
BRPI9910024B8 (en) use of a mixture of sugar alcohols containing 6-o-alpha-d-glycopyranosyl-d-sorbitol (1,6-gps) and 1-o-alpha-d-glycopyranosyl-d-mannitol (1,1-gpm) in vitro, and pharmaceutical composition for human or animal consumption
AU9363398A (en) Hepatitis c receptor protein cd81
Purushotham et al. Absorption of epidermal growth factor occurs through the gastrointestinal tract and oral cavity in adult rats